查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2094795

醫藥低溫運輸市場－全球市場預測（2026-2032年）

Cold-chain Pharma Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫藥低溫運輸市場規模將達到 314.7 億美元，複合年成長率為 9.39%。

主要市場統計數據
基準年 2025 167.8億美元
預計年份：2026年 182.8億美元
預測年份：2032年 314.7億美元
複合年成長率 (%) 9.39%

醫藥低溫運輸市場執行摘要

生物製藥、疫苗、細胞和基因療法、胰島素、血液製品、臨床實驗室耗材以及對溫度敏感的特藥，從生產到患者用藥的整個過程都需要嚴格的控制，這使得藥品低溫運輸成為全球醫療物流的關鍵支柱。該領域的特點是：溫度控制、檢驗的包裝、合格良好分銷規範 (GDP) 的分銷、路線驗證、即時監控以及在冷藏、冷凍、超低溫和低溫條件下的異常管理。生物製藥研發管線的日益複雜、免疫接種計劃的擴展、臨床實驗室檢測的去中心化以及對產品完整性日益嚴格的監管，都在推動對高可靠性藥品低溫運輸物流的需求。經營團隊重點也從單純的冷藏保管能力轉向端到端的可視性、數位化溫度監控、認證的物流合作夥伴、永續包裝以及基於風險的品管。在這種環境下，藥品低溫運輸不再只是後勤部門物流功能，而是一項戰略能力，它能夠保護病人安全、減少產品損失、支持監管合規，並使已開發國家和新興國家的醫療保健系統都能獲得先進的治療方法。

醫藥低溫運輸產業的變革

隨著醫療供應鏈不斷適應更精細的療法、更嚴格的合規要求以及日益動盪的營運環境，藥品低溫運輸格局正在改變。生技藥品和生物相似藥需要在日益全球化的運輸路線中保持穩定的溫度控制，而mRNA平台、特種注射劑以及細胞和基因療法則對超低溫和低溫物流提出了更高的要求。諸如藥品良好分銷規範（GDP）、藥品安全監測要求、序列化以及記錄在案的儲存歷史等法律規範，迫使各機構檢驗流程、合格運輸路線並維護可審計的溫度記錄。同時，地緣政治不穩定、複雜的海關程序、能源成本波動以及極端天氣事件，使得制定緊急時應對計畫和進行運輸路線風險評估至關重要。此外，採購系統也正從永續發展的角度進行重組，人們越來越關注可重複使用的被動式包裝、低排放運輸方式、整合最佳化的運輸以及可回收的隔熱材料。各行業正從被動的溫度偏差管理轉向感測器驅動的主動控制塔，從而實現統一的營運模式，整合包裝、運輸、儲存、品質保證和監管文件。

人工智慧對藥品低溫運輸的累積影響

人工智慧 (AI) 透過提升預測可視性、營運彈性和決策質量，對醫藥低溫運輸的影響日益顯著。 AI 驅動的分析可以評估歷史運輸路線績效、天氣模式、海關延誤、承運商可靠性、環境溫度暴露情況以及包裝合格數據，從而支援裝運前路線選擇和風險評分。機器學習模型有助於識別溫度偏差、設備故障和交付延誤的早期預警訊號，使品管團隊能夠在產品完整性受損之前進行干預。在倉儲和運輸營運中，AI 可以幫助實現基於需求的庫存分配自動化、冷藏集裝箱的動態利用、冷凍設備的預測性維護以及異常情況的優先排序。在臨床實驗室供應鏈和高價值生技藥品領域，AI 驅動的協調可以透過協調批次放行、患者預約和最後一公里配送時間來減少廢棄物。然而，AI 的實施需要強大的資料管治、檢驗的數位系統、網路安全措施、可解釋的演算法以及對 GxP 要求的遵守。人工智慧的累積影響使得製藥業的低溫運輸管理從靜態的合規文件轉變為持續的、智慧主導的保障系統。

區域藥品低溫運輸關鍵洞察

由於中國、印度、日本、韓國、澳洲和東協等國生物製藥生產的擴張、大規模疫苗接種基礎設施的完善、專科藥物使用量的增加以及臨床研究活動的活性化，亞太地區對藥品低溫運輸的重要性日益凸顯。然而，該地區的機會也受到法規環境差異、區域內運輸路線漫長、氣候潮濕以及冷藏保管成熟度不一等因素的限制，因此，認證包裝和溫度可視性至關重要。北美仍然是藥品低溫運輸物流最先進的地區之一，這得益於美國和加拿大成熟的生物製藥分銷體系、專科藥房網路、完善的臨床實驗室基礎設施以及高普及率的數位化監控。同時，涉及墨西哥的跨境物流湧入進一步凸顯了文件協調和報關準備的重要性。在拉丁美洲，公共免疫計劃、私人專科醫療保健和區域藥品分銷網路的擴展正在增強低溫運輸能力。然而，基礎設施短缺、海關延誤和最後一公里配送的不確定性，使得制定強力的緊急時應對計畫尤為重要，尤其是在巴西和墨西哥。歐洲擁有嚴格的GDP標準、高密度的多模態物流走廊以及許多市場統一的高層監管，但與英國脫歐相關的繁瑣手續、跨境溫控以及永續性法規等問題仍在影響著其營運模式。中東正逐步成為航空貨運和醫療物流的戰略樞紐，海灣合作理事會（GCC）正在投資建造溫控倉庫、機場自由區和藥品進口基礎設施。非洲是疫苗分發、基本藥物和捐助者支持的醫療計畫的重要地區，但其低溫運輸的可靠性很大程度上依賴於對能源韌性、訓練有素的人員、檢驗的最後一公里配送以及區域倉儲網路的投資。

主要經濟和戰略群體的見解

由於醫療保健覆蓋範圍的擴大、區域內製造業活動的活性化以及對疫苗、胰島素、生技藥品和專科藥物需求的成長，東協在藥品低溫運輸中的重要性日益凸顯。然而，由於島嶼地區的區域性特徵、熱帶氣候、不同的海關程序以及基礎設施的差異，運輸路線的合格和「最後一公里」的溫度控制是成功的關鍵。海灣合作理事會（GCC）正在發展成為高價值藥品物流的門戶，這得益於其在航空貨運、醫療基礎設施、自由區配送和先進冷藏倉儲方面的投資。進口專科藥物和政府主導的醫療現代化推動了這項需求。歐盟透過統一的藥品良好儲存標準（GDP）要求、強力的法律規範、密集的跨境公路貨運以及對永續物流日益成長的重視，提供了結構最完善的低溫運輸運營環境之一，並將合規文件、溫度分佈圖和檢驗的運輸系統作為標準要求。金磚國家擁有大規模的患者群體，國內藥品生產不斷成長，生物製藥的應用也日益普及，但由於氣候、監管力度、基礎設施成熟度和區域醫療服務可及性等方面的差異，其低溫運輸需求存在顯著差異。七國集團（G7）國家憑藉其完善的醫療體系、成熟的專業藥品分銷網路和嚴格的品質保證標準，在建立先進的低溫運輸實踐方面仍然發揮著重要作用。北約成員國，特別是歐洲和北美成員國，透過建構具有韌性的物流走廊、軍民兩用基礎設施、緊急準備以及跨境合作，在藥品低溫運輸中發揮著至關重要的作用，即使在公共衛生緊急事件和地緣政治動盪時期，也能確保對溫度敏感的醫療用品的持續供應。

低溫運輸藥品關鍵國家概況

美國憑藉其大規模的特種藥品生態系統、生技藥品分銷網路、臨床試驗活動以及即時監控的廣泛應用，在先進的藥品低溫運輸能力方面處於主導地位。同時，加拿大由於人口分散且季節性溫差較大，因此格外重視包裝驗證和區域分銷規劃。墨西哥正透過近岸外包、生產活動和跨境貿易來加強其在北美藥品物流中的作用，但海關協調和運輸路線的可靠性仍然是重大挑戰。巴西滿足了拉丁美洲對疫苗、生技藥品和特殊療法的需求，但區域基礎設施的差異需要精心設計網路。在歐洲，英國即使在脫歐後貿易環境變化的情況下，仍然優先考慮合規的藥品分銷。德國憑藉著強勁的GDP成長，維持了作為物流和製造核心樞紐的地位。法國支持大規模的醫療保健和疫苗分銷活動。義大利和西班牙將國內藥品生產與日益成長的特殊療法需求相結合。此外，俄羅斯幅員遼闊，氣候條件極端，因此對強大的冷藏保管設施和遠距離溫控的需求日益成長。在亞太地區，中國生物製藥製造地的擴張、疫苗生產能力的提升以及醫療衛生現代化，都對國內低溫運輸提出了更高的要求。同時，在印度，疫苗、臨床研究活動和生物製藥的日益普及，推動了對可靠的冷藏和冷凍配送的需求。日本嚴格的醫療體系和高標準的文化，為嚴格的低溫運輸合規提供了保障。澳洲需要強大的、覆蓋全國的遠距離配送方案，而韓國的生物製藥生產能力和數位化基礎設施，則為國內和出口市場提供了高度溫控的物流支援。

醫藥低溫運輸。

產業領導者應將藥品低溫運輸視為一個整合品管和風險管理的環節，而不僅僅是運輸和採購環節。優先行動包括：檢驗所有關鍵運輸路線，繪製季節性和特定路線的溫度風險圖，合格包裝是否符合實際運輸條件，以及製定清晰的標準操作規程 (SOP)，以應對溫度偏差、海關延誤和交付失敗等情況。各組織應投資於可互通的資料系統，以支援即時溫度和位置監控、控制塔視覺化、預測分析和可稽核的合規性。供應商合格評估不僅應考慮成本和覆蓋範圍，還應評估其良好產品分銷 (GDP) 成熟度、員工培訓、設備校準、緊急應變能力、網路安全以及已記錄的糾正措施。領導者還應透過雙路線、備用儲存設施、不間斷電源、多元化的承運商網路以及關鍵藥品的本地緊急儲備來增強韌性。永續性目標應融入低溫運輸設計，具體措施包括使用可重複使用的運輸容器、最佳化裝載密度、盡可能選擇低排放運輸方式以及對包裝進行生命週期評估。對於高價值生技藥品、細胞和基因療法以及臨床診斷材料，品質、供應鏈、法規、生產和患者服務部門之間的跨部門合作對於保障產品完整性和治療的連續性至關重要。

調查方法

本執行摘要採用系統性的二手研究方法編寫，重點關注與藥品低溫運輸物流、醫療保健供應鏈、法規遵從以及溫敏藥品分銷相關的、經過檢驗的、公開可用的且行業認可的資訊來源。該調查方法強調對監管指南、公共衛生物流文件、藥品分銷標準、關稅和貿易考慮、基礎設施評估、臨床供應鏈實踐以及技術應用模式檢驗研究途徑驗證。透過檢驗多個可靠資訊來源類別（包括衛生監管機構、物流標準化機構、貿易文件、同行評審的供應鏈文獻和公共政策材料）中的通用主題，驗證研究結果。本分析不涉及市場規模、市場佔有率和預測，而是專注於營運促進因素、區域趨勢、合規要求、技術影響和策略措施。該框架優先考慮對冷藏、冷凍、超低溫和低溫物流的低溫運輸要求進行循證解讀，同時兼顧品質保證、韌性、永續性和數位轉型。

結論

藥品低溫運輸正步入一個新階段，其特點是生物製藥的成長、日益嚴格的合規要求、數位化視覺化、人工智慧驅動的風險管理以及對具有韌性的全球醫療物流的需求。在複雜的運輸路線中保持產品完整性的能力與患者安全、監管機構的信任以及獲得先進治療方案的機會直接相關。由於基礎設施、氣候、法規和醫療服務體系在區域和國家層級存在差異，因此需要針對不同情況制定個人化最佳化的低溫運輸策略，而非採用統一的配送模式。那些能夠將經過檢驗的流程、即時監控、合格的合作夥伴、永續的包裝以及積極主動的緊急時應對計畫相結合的機構，更有可能在日益嚴峻的環境中有效地管理對溫度敏感的藥品。隨著藥品組合日益專業化，供應鏈面臨更大的中斷風險​​，卓越的低溫運輸管理仍將是實現可靠、合規且以患者為中心的醫療服務的核心差異化因素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 醫藥低溫運輸市場：依產品類型分類

  • 生物製劑
    • 單株抗體
    • 血漿衍生療法
    • 重組蛋白質和酶
  • 血液和血漿製品
    • 凝血因子
    • 免疫球蛋白
  • 細胞和基因治療
    • 異體細胞療法
    • 自體細胞療法
    • 基因治療
  • 臨床試驗用材料
    • 配件和套裝
    • 臨床實驗藥物
  • 胰島素和荷爾蒙
    • GLP-1 和其他胜肽激素
    • 胰島素
  • 特種藥品
    • 不孕症和生殖醫學
    • 特殊注射藥物
  • 疫苗
    • 大流行和新興疫苗
      • 藥效疫苗
      • 病毒載體疫苗
    • 常規免疫疫苗
    • 旅行和特殊疫苗

第8章：藥品低溫運輸市場：依包裝類型分類

  • 活性包裝
  • 被動式包裝

第9章：醫藥低溫運輸市場：依溫度範圍分類

  • 低溫（低於-150 度C）
    • 冷凍包裝
    • 乾貨運輸
    • 液態氮蒸氣儲存
  • 冷凍（約 20 至 -40 度C）
    • 包裝
    • 貯存
    • 運輸
  • 冷藏（2-8 度C）
    • 包裝
    • 貯存
    • 運輸
  • 超低溫（-60 至 -86 度C）
    • 包裝
    • 貯存
    • 運輸

第10章：醫藥低溫運輸市場：依設備分類

  • 儲存裝置
    • 冷藏室和倉庫
    • 低溫冷凍庫和液態氮冷卻罐
    • 冷凍庫（20 度C級）
    • 醫藥冷藏庫（2-8 度C）
    • 超低溫冰箱（-80 度C）
  • 運輸設備
    • 航空貨運貨櫃（ULD）
    • 最後一公里用的可攜式冷藏箱
    • 冷藏運輸貨櫃
    • 冷藏卡車和廂型車

第11章 醫藥低溫運輸市場：依服務類型分類

  • 臨床實驗室物流
    • 輔助管理
    • 為患者提供直接服務
    • 向臨床實驗點供應和退貨
  • 合規性和品質
    • 審計和GDP培訓
    • 線路檢驗和風險評估
    • 資格確認（IQ/OQ/PQ）
  • 倉儲管理
    • 低溫儲存
    • 長期GMP儲存
  • 運輸
    • 首英里接送
    • 最後一公里配送
    • 長途
    • 逆向物流和退貨

第12章 醫藥低溫運輸市場：依應用領域分類

  • 臨床試驗
  • 商業分銷
  • 直接送達/宅配患者
  • 向非政府組織提供人道援助和物資
  • 為專業藥局提供履約
  • 疫苗宣傳活動

第13章 醫藥低溫運輸市場：依最終用戶分類

  • 血庫和血漿中心
  • 臨床試驗設施及儲存場所
  • CMO 和 CDMO
  • CRO
  • 醫院和診所
  • 製藥和生物技術製造商
    • 新興生技公司
    • 大型製藥公司
  • 零售藥局和專科藥局
  • 疫苗接種中心和公共衛生機構

第14章 醫藥低溫運輸市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：醫藥低溫運輸市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 藥品低溫運輸市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Americold Realty Trust, Inc.
  • AmerisourceBergen Corporation
  • BioCold Technologies SAS
  • CH Robinson Worldwide, Inc.
  • Catalent, Inc.
  • Clinigen Group PLC
  • Conestoga Cold Storage Ltd.
  • Continental AG
  • CWT Ltd.
  • DB Schenker
  • DHL International GmbH
  • DSV A/S
  • Emergent Cold LatAm Management LLC
  • FedEx Corporation
  • FreezPak Logistics
  • HCL Technologies Limited
  • Helapet ltd.
  • Interstate Cold Storage, Inc.
  • JWD InfoLogistics Public Co. Ltd.
  • Keppel Telecommunications & Transportation Ltd
  • Kuehne+Nagel Management AG
  • Lineage, Inc.
  • Maersk A/S
  • NewCold Cooperatief UA
  • OOCL Logistics Limited（COSCO SHIPPING Holdings Co. Limited）
  • SCG Logistics Management Co Ltd.
  • Tiong Nam Logistics Holdings Berhad
  • United Parcel Service, Inc.
  • Ych Group
  • Yusen Logistics Group
Product Code: MRR-7E6E70985BD9

The Cold-chain Pharma Market is projected to grow by USD 31.47 billion at a CAGR of 9.39% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.78 billion
Estimated Year [2026] USD 18.28 billion
Forecast Year [2032] USD 31.47 billion
CAGR (%) 9.39%

Cold-Chain Pharma Executive Summary

Cold-chain pharma has become a mission-critical pillar of global healthcare logistics as biologics, vaccines, cell and gene therapies, insulin, blood products, clinical trial materials, and temperature-sensitive specialty medicines require tightly controlled handling from manufacture to patient administration. The sector is defined by temperature assurance, validated packaging, Good Distribution Practice-compliant distribution, lane qualification, real-time monitoring, and exception management across refrigerated, frozen, deep-frozen, and cryogenic conditions. Demand for resilient pharmaceutical cold chain logistics is being reinforced by the growing complexity of biologic drug pipelines, wider immunization programs, decentralization of clinical trials, and stricter regulatory scrutiny over product integrity. Executive priorities are shifting from simple cold storage capacity toward end-to-end visibility, digital temperature monitoring, qualified logistics partners, sustainable packaging, and risk-based quality management. In this environment, cold-chain pharma is no longer a back-office logistics function; it is a strategic capability that protects patient safety, reduces product loss, supports regulatory compliance, and enables access to advanced therapies across developed and emerging healthcare systems.

Transformative Shifts in the Cold-Chain Pharma Landscape

The cold-chain pharma landscape is undergoing transformative change as healthcare supply chains adapt to more sensitive therapies, more stringent compliance expectations, and more volatile operating conditions. Biologics and biosimilars require stable temperature control across increasingly globalized routes, while mRNA platforms, specialty injectables, and cell and gene therapies are raising requirements for ultra-low-temperature and cryogenic logistics. Regulatory frameworks such as Good Distribution Practice, pharmacovigilance expectations, serialization, and documented chain of custody are pushing organizations to validate processes, qualify shipping lanes, and maintain auditable temperature records. At the same time, geopolitical disruption, customs complexity, energy cost volatility, and extreme weather events are making contingency planning and route risk assessment essential. Sustainability is also reshaping procurement, with reusable passive packaging, lower-emission transport modes, optimized shipment consolidation, and recyclable insulation materials gaining attention. The industry is moving from reactive temperature excursion management to proactive, sensor-enabled control towers that integrate packaging, transport, storage, quality assurance, and regulatory documentation into a unified operating model.

Cumulative Impact of Artificial Intelligence on Cold-Chain Pharma

Artificial intelligence is increasingly influencing cold-chain pharma by improving predictive visibility, operational resilience, and quality decision-making. AI-enabled analytics can assess historical lane performance, weather patterns, customs delays, carrier reliability, ambient temperature exposure, and packaging qualification data to support route selection and risk scoring before shipment release. Machine learning models help identify early warning signals for temperature excursions, equipment failures, and delayed handoffs, enabling quality teams to intervene before product integrity is compromised. In warehouse and transport operations, AI can support demand-sensitive inventory positioning, dynamic reefer utilization, predictive maintenance for refrigeration assets, and automated exception prioritization. For clinical trial supply chains and high-value biologics, AI-driven orchestration can reduce waste by aligning batch release, patient scheduling, and last-mile delivery windows. However, adoption requires strong data governance, validated digital systems, cybersecurity controls, explainable algorithms, and alignment with GxP expectations. The cumulative impact of AI is the transition of pharmaceutical cold chain management from static compliance documentation to continuous, intelligence-led assurance.

Key Regional Insights Across Cold-Chain Pharma

Asia-Pacific is becoming a crucial cold-chain pharma region due to expanding biologics manufacturing, large-scale vaccination infrastructure, rising specialty medicine use, and the growth of clinical research activity across China, India, Japan, South Korea, Australia, and ASEAN economies. The region's opportunity is balanced by diverse regulatory environments, long intra-regional transit lanes, humid climates, and varying cold storage maturity, making qualified packaging and temperature visibility essential. North America remains one of the most advanced environments for pharmaceutical cold chain logistics, supported by mature biologics distribution, specialty pharmacy networks, established clinical trial infrastructure, and high adoption of digital monitoring across the United States and Canada, while cross-border flows involving Mexico increase the importance of harmonized documentation and customs readiness. Latin America is strengthening cold-chain capabilities as public immunization programs, private specialty care, and regional pharmaceutical distribution networks expand, though infrastructure gaps, customs delays, and last-mile variability require robust contingency planning, particularly across Brazil and Mexico. Europe benefits from stringent GDP standards, dense multimodal logistics corridors, and high regulatory harmonization across many markets, while Brexit-related documentation, cross-border temperature assurance, and sustainability mandates continue to shape operating models. The Middle East is positioning itself as a strategic air cargo and healthcare logistics hub, with GCC economies investing in temperature-controlled warehousing, airport free zones, and pharmaceutical import infrastructure. Africa presents a high-impact environment for vaccine distribution, essential medicines, and donor-supported healthcare programs, but cold-chain reliability is highly dependent on energy resilience, trained personnel, validated last-mile delivery, and investment in regional storage networks.

Key Economic and Strategic Group Insights

ASEAN is increasingly important for cold-chain pharma due to its expanding healthcare access, regional manufacturing activity, and rising demand for vaccines, insulin, biologics, and specialty medicines; however, island geographies, tropical climates, customs variation, and uneven infrastructure make lane qualification and last-mile temperature control central to success. The GCC is developing into a high-value pharmaceutical logistics gateway, supported by investments in air cargo, healthcare infrastructure, free-zone distribution, and advanced cold storage, with demand shaped by imported specialty medicines and government-led healthcare modernization. The European Union provides one of the most structured cold-chain operating environments through harmonized GDP expectations, strong regulatory oversight, cross-border road freight density, and increasing emphasis on sustainable logistics, making compliance documentation, temperature mapping, and validated transport systems standard requirements. BRICS countries combine large patient populations, expanding domestic pharmaceutical production, and rising biologics adoption, but their cold-chain requirements vary widely due to differences in climate, regulatory enforcement, infrastructure maturity, and rural healthcare access. G7 economies remain influential in setting advanced cold-chain practices because they host sophisticated healthcare systems, mature specialty pharmaceutical distribution, and strong quality assurance expectations. NATO member countries, particularly those in Europe and North America, are relevant to cold-chain pharma through resilient logistics corridors, dual-use infrastructure, emergency preparedness, and cross-border coordination that can support continuity of temperature-sensitive medical supplies during public health emergencies or geopolitical disruption.

Key Country Insights in Cold-Chain Pharma

The United States leads in advanced cold-chain pharma capabilities due to its large specialty medicine ecosystem, biologics distribution networks, clinical trial activity, and broad use of real-time monitoring, while Canada's dispersed population and seasonal temperature extremes make packaging validation and regional distribution planning especially important. Mexico is strengthening its role in North American pharmaceutical logistics through nearshoring, manufacturing activity, and cross-border trade, although customs coordination and lane reliability remain critical. Brazil anchors Latin American demand for vaccine distribution, biologics, and specialty therapies, with infrastructure differences across regions requiring careful network design. In Europe, the United Kingdom continues to emphasize compliant pharmaceutical distribution after Brexit-related trade changes, Germany remains a central logistics and manufacturing hub with strong GDP discipline, France supports significant healthcare and vaccine distribution activity, Italy and Spain combine domestic pharmaceutical production with growing specialty medicine demand, and Russia's vast geography and climatic extremes increase the need for resilient cold storage and long-distance temperature assurance. In Asia-Pacific, China's expanding biologics production, vaccine capabilities, and healthcare modernization are strengthening domestic cold-chain requirements, while India's vaccine manufacturing base, clinical research activity, and growing biologics use intensify the need for reliable refrigerated and frozen distribution. Japan's highly regulated healthcare system and advanced quality culture support stringent cold-chain compliance, Australia's geography requires robust national distribution planning across long distances, and South Korea's biologics manufacturing strength and digital infrastructure support sophisticated temperature-controlled logistics for domestic and export markets.

Actionable Recommendations for Cold-Chain Pharma Leaders

Industry leaders should treat cold-chain pharma as an integrated quality and risk management discipline rather than a transport procurement category. Priority actions include validating every critical lane, mapping temperature risk by season and route, qualifying packaging for real-world transit conditions, and establishing clear standard operating procedures for excursions, customs delays, and handoff failures. Organizations should invest in real-time temperature and location monitoring, control tower visibility, predictive analytics, and interoperable data systems that support auditable compliance. Supplier qualification should assess not only cost and coverage but also GDP maturity, staff training, equipment calibration, contingency capacity, cybersecurity, and documented corrective action performance. Leaders should also build resilience through dual routing, backup storage, emergency power, diversified carrier networks, and local contingency inventories for critical medicines. Sustainability goals should be embedded into cold-chain design through reusable shippers, optimized payload density, lower-emission transport choices where feasible, and packaging lifecycle assessments. For high-value biologics, cell and gene therapies, and clinical trial materials, cross-functional coordination between quality, supply chain, regulatory, manufacturing, and patient services is essential to protect product integrity and treatment continuity.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, publicly available, and industry-recognized sources related to pharmaceutical cold chain logistics, healthcare supply chains, regulatory compliance, and temperature-sensitive medicine distribution. The methodology emphasizes qualitative triangulation across regulatory guidance, public health logistics documentation, pharmaceutical distribution standards, customs and trade considerations, infrastructure assessments, clinical supply chain practices, and technology adoption patterns. Insights are validated by comparing recurring themes across multiple credible source categories, including health authorities, logistics standards bodies, trade documentation, peer-reviewed supply chain literature, and public policy materials. The analysis excludes market sizing, market share, and forecasting, and instead focuses on operational drivers, regional dynamics, compliance requirements, technology implications, and strategic actions. The framework prioritizes evidence-based interpretation of cold-chain requirements across refrigerated, frozen, ultra-low-temperature, and cryogenic logistics, with attention to quality assurance, resilience, sustainability, and digital transformation.

Conclusion

Cold-chain pharma is entering a new phase defined by biologics growth, stricter compliance expectations, digital visibility, AI-supported risk management, and the need for resilient global healthcare logistics. The ability to maintain product integrity across complex routes is directly linked to patient safety, regulatory confidence, and access to advanced therapies. Regional and country-level differences in infrastructure, climate, regulation, and healthcare delivery require tailored cold-chain strategies rather than one-size-fits-all distribution models. Organizations that combine validated processes, real-time monitoring, qualified partners, sustainable packaging, and proactive contingency planning will be better positioned to manage temperature-sensitive medicines in an increasingly demanding environment. As pharmaceutical portfolios become more specialized and supply chains face greater disruption, cold-chain excellence will remain a core differentiator for reliable, compliant, and patient-centered healthcare delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cold-chain Pharma Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Monoclonal Antibodies
    • 7.2.2. Plasma-Derived Therapeutics
    • 7.2.3. Recombinant Proteins & Enzymes
  • 7.3. Blood & Plasma Products
    • 7.3.1. Coagulation Factors
    • 7.3.2. Immunoglobulins
  • 7.4. Cell & Gene Therapies
    • 7.4.1. Allogeneic Cell Therapies
    • 7.4.2. Autologous Cell Therapies
    • 7.4.3. Gene Therapies
  • 7.5. Clinical Trial Materials
    • 7.5.1. Ancillaries & Kits
    • 7.5.2. Investigational Medicinal Products
  • 7.6. Insulins & Hormones
    • 7.6.1. GLP-1 & Other Peptide Hormones
    • 7.6.2. Insulin
  • 7.7. Specialty Pharmaceuticals
    • 7.7.1. Fertility & Reproductive Medicines
    • 7.7.2. Specialty Injectables
  • 7.8. Vaccines
    • 7.8.1. Pandemic & Emerging Vaccines
      • 7.8.1.1. mRNA Vaccines
      • 7.8.1.2. Viral Vector Vaccines
    • 7.8.2. Routine Immunization Vaccines
    • 7.8.3. Travel & Specialty Vaccines

8. Cold-chain Pharma Market, by Packaging Type

  • 8.1. Introduction
  • 8.2. Active Packaging
  • 8.3. Passive Packaging

9. Cold-chain Pharma Market, by Temperature Range

  • 9.1. Introduction
  • 9.2. Cryogenic (<= -150 °C)
    • 9.2.1. Cryo Packaging
    • 9.2.2. Dry Shipper Transport
    • 9.2.3. LN2 Vapor Storage
  • 9.3. Frozen (-20 To -40 °C)
    • 9.3.1. Packaging
    • 9.3.2. Storage
    • 9.3.3. Transportation
  • 9.4. Refrigerated (2-8 °C)
    • 9.4.1. Packaging
    • 9.4.2. Storage
    • 9.4.3. Transportation
  • 9.5. Ultra-Low (-60 To -86 °C)
    • 9.5.1. Packaging
    • 9.5.2. Storage
    • 9.5.3. Transportation

10. Cold-chain Pharma Market, by Equipment

  • 10.1. Introduction
  • 10.2. Storage Equipment
    • 10.2.1. Cold Rooms & Warehouses
    • 10.2.2. Cryogenic Freezers & LN2 Tanks
    • 10.2.3. Freezers (-20 °C Class)
    • 10.2.4. Pharmaceutical Refrigerators (2-8 °C)
    • 10.2.5. ULT Freezers (-80 °C Class)
  • 10.3. Transport Equipment
    • 10.3.1. Air Cargo Containers (ULDs)
    • 10.3.2. Last-Mile Portable Coolers
    • 10.3.3. Ocean Reefer Containers
    • 10.3.4. Reefer Trucks & Vans

11. Cold-chain Pharma Market, by Service Type

  • 11.1. Introduction
  • 11.2. Clinical Trial Logistics
    • 11.2.1. Ancillary Management
    • 11.2.2. Direct-To-Patient Services
    • 11.2.3. Site Supply And Returns
  • 11.3. Compliance & Quality
    • 11.3.1. Audits & GDP Training
    • 11.3.2. Lane Validation & Risk Assessment
    • 11.3.3. Qualification (IQ/OQ/PQ)
  • 11.4. Storage & Warehousing
    • 11.4.1. Cryogenic Storage
    • 11.4.2. Long-Term GMP Storage
  • 11.5. Transportation
    • 11.5.1. First-Mile Pickup
    • 11.5.2. Last-Mile Delivery
    • 11.5.3. Line-Haul Transport
    • 11.5.4. Reverse Logistics & Returns

12. Cold-chain Pharma Market, by Application

  • 12.1. Introduction
  • 12.2. Clinical Trials
  • 12.3. Commercial Distribution
  • 12.4. Direct-To-Patient/Home Delivery
  • 12.5. Humanitarian & NGO Supply
  • 12.6. Specialty Pharmacy Fulfillment
  • 12.7. Vaccination Campaigns

13. Cold-chain Pharma Market, by End User

  • 13.1. Introduction
  • 13.2. Blood Banks & Plasma Centers
  • 13.3. Clinical Trial Sites & Depots
  • 13.4. CMOs & CDMOs
  • 13.5. CROs
  • 13.6. Hospitals & Clinics
  • 13.7. Pharma & Biotech Manufacturers
    • 13.7.1. Emerging Biotech
    • 13.7.2. Large Pharmaceutical Companies
  • 13.8. Retail & Specialty Pharmacies
  • 13.9. Vaccination Centers & Public Health Agencies

14. Cold-chain Pharma Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Cold-chain Pharma Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cold-chain Pharma Market, by Country

  • 16.1. United States
  • 16.2. China
  • 16.3. Germany
  • 16.4. United Kingdom
  • 16.5. India
  • 16.6. Japan
  • 16.7. Russia
  • 16.8. Brazil
  • 16.9. Canada
  • 16.10. Italy
  • 16.11. Mexico
  • 16.12. France
  • 16.13. Spain
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Americold Realty Trust, Inc.
  • 18.2. AmerisourceBergen Corporation
  • 18.3. BioCold Technologies S.A.S
  • 18.4. C.H. Robinson Worldwide, Inc.
  • 18.5. Catalent, Inc.
  • 18.6. Clinigen Group PLC
  • 18.7. Conestoga Cold Storage Ltd.
  • 18.8. Continental AG
  • 18.9. CWT Ltd.
  • 18.10. DB Schenker
  • 18.11. DHL International GmbH
  • 18.12. DSV A/S
  • 18.13. Emergent Cold LatAm Management LLC
  • 18.14. FedEx Corporation
  • 18.15. FreezPak Logistics
  • 18.16. HCL Technologies Limited
  • 18.17. Helapet ltd.
  • 18.18. Interstate Cold Storage, Inc.
  • 18.19. JWD InfoLogistics Public Co. Ltd.
  • 18.20. Keppel Telecommunications & Transportation Ltd,
  • 18.21. Kuehne + Nagel Management AG
  • 18.22. Lineage, Inc.
  • 18.23. Maersk A/S
  • 18.24. NewCold Cooperatief UA
  • 18.25. OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
  • 18.26. SCG Logistics Management Co Ltd.
  • 18.27. Tiong Nam Logistics Holdings Berhad
  • 18.28. United Parcel Service, Inc.
  • 18.29. Ych Group
  • 18.30. Yusen Logistics Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLD-CHAIN PHARMA MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL COLD-CHAIN PHARMA MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL COLD-CHAIN PHARMA MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL COLD-CHAIN PHARMA MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COLD-CHAIN PHARMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL COLD-CHAIN PHARMA MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL COLD-CHAIN PHARMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLASMA-DERIVED THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMA-DERIVED THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PLASMA-DERIVED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RECOMBINANT PROTEINS & ENZYMES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RECOMBINANT PROTEINS & ENZYMES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RECOMBINANT PROTEINS & ENZYMES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD & PLASMA PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD & PLASMA PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD & PLASMA PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COAGULATION FACTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COAGULATION FACTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COAGULATION FACTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNOGLOBULINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ALLOGENEIC CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ALLOGENEIC CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ALLOGENEIC CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOLOGOUS CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CLINICAL TRIAL MATERIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CLINICAL TRIAL MATERIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICAL TRIAL MATERIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANCILLARIES & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANCILLARIES & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANCILLARIES & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INVESTIGATIONAL MEDICINAL PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INVESTIGATIONAL MEDICINAL PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INVESTIGATIONAL MEDICINAL PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSULINS & HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSULINS & HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSULINS & HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLP-1 & OTHER PEPTIDE HORMONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GLP-1 & OTHER PEPTIDE HORMONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLP-1 & OTHER PEPTIDE HORMONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SPECIALTY PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FERTILITY & REPRODUCTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FERTILITY & REPRODUCTIVE MEDICINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FERTILITY & REPRODUCTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SPECIALTY INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SPECIALTY INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SPECIALTY INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PANDEMIC & EMERGING VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PANDEMIC & EMERGING VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PANDEMIC & EMERGING VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL VECTOR VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ROUTINE IMMUNIZATION VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ROUTINE IMMUNIZATION VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ROUTINE IMMUNIZATION VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRAVEL & SPECIALTY VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TRAVEL & SPECIALTY VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRAVEL & SPECIALTY VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ACTIVE PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PASSIVE PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CRYOGENIC (<= -150 °C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRYOGENIC (<= -150 °C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CRYOGENIC (<= -150 °C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRYO PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CRYO PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRYO PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRY SHIPPER TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRY SHIPPER TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRY SHIPPER TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LN2 VAPOR STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LN2 VAPOR STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL LN2 VAPOR STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FROZEN (-20 TO -40 °C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL FROZEN (-20 TO -40 °C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL FROZEN (-20 TO -40 °C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSPORTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TRANSPORTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSPORTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL REFRIGERATED (2-8 °C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL REFRIGERATED (2-8 °C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL REFRIGERATED (2-8 °C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSPORTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TRANSPORTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSPORTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ULTRA-LOW (-60 TO -86 °C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ULTRA-LOW (-60 TO -86 °C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ULTRA-LOW (-60 TO -86 °C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PACKAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PACKAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PACKAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSPORTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL TRANSPORTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSPORTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL STORAGE EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL STORAGE EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL STORAGE EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL COLD ROOMS & WAREHOUSES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL COLD ROOMS & WAREHOUSES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL COLD ROOMS & WAREHOUSES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRYOGENIC FREEZERS & LN2 TANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CRYOGENIC FREEZERS & LN2 TANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRYOGENIC FREEZERS & LN2 TANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL FREEZERS (-20 °C CLASS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL FREEZERS (-20 °C CLASS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL FREEZERS (-20 °C CLASS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PHARMACEUTICAL REFRIGERATORS (2-8 °C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PHARMACEUTICAL REFRIGERATORS (2-8 °C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PHARMACEUTICAL REFRIGERATORS (2-8 °C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ULT FREEZERS (-80 °C CLASS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ULT FREEZERS (-80 °C CLASS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ULT FREEZERS (-80 °C CLASS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL TRANSPORT EQUIPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TRANSPORT EQUIPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL TRANSPORT EQUIPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL AIR CARGO CONTAINERS (ULDS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL AIR CARGO CONTAINERS (ULDS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL AIR CARGO CONTAINERS (ULDS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL LAST-MILE PORTABLE COOLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL LAST-MILE PORTABLE COOLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL LAST-MILE PORTABLE COOLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL OCEAN REEFER CONTAINERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL OCEAN REEFER CONTAINERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL OCEAN REEFER CONTAINERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL REEFER TRUCKS & VANS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL REEFER TRUCKS & VANS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL REEFER TRUCKS & VANS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CLINICAL TRIAL LOGISTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CLINICAL TRIAL LOGISTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CLINICAL TRIAL LOGISTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ANCILLARY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANCILLARY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ANCILLARY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL DIRECT-TO-PATIENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL DIRECT-TO-PATIENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL DIRECT-TO-PATIENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SITE SUPPLY AND RETURNS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL SITE SUPPLY AND RETURNS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL SITE SUPPLY AND RETURNS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL COMPLIANCE & QUALITY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL COMPLIANCE & QUALITY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL COMPLIANCE & QUALITY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL AUDITS & GDP TRAINING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUDITS & GDP TRAINING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL AUDITS & GDP TRAINING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL LANE VALIDATION & RISK ASSESSMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL LANE VALIDATION & RISK ASSESSMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL LANE VALIDATION & RISK ASSESSMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL QUALIFICATION (IQ/OQ/PQ) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL QUALIFICATION (IQ/OQ/PQ) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL QUALIFICATION (IQ/OQ/PQ) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL STORAGE & WAREHOUSING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL STORAGE & WAREHOUSING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL STORAGE & WAREHOUSING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CRYOGENIC STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CRYOGENIC STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CRYOGENIC STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL LONG-TERM GMP STORAGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL LONG-TERM GMP STORAGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL LONG-TERM GMP STORAGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL TRANSPORTATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL TRANSPORTATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL TRANSPORTATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL FIRST-MILE PICKUP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL FIRST-MILE PICKUP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL FIRST-MILE PICKUP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL LAST-MILE DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL LAST-MILE DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL LAST-MILE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL LINE-HAUL TRANSPORT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL LINE-HAUL TRANSPORT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL LINE-HAUL TRANSPORT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL REVERSE LOGISTICS & RETURNS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL REVERSE LOGISTICS & RETURNS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL REVERSE LOGISTICS & RETURNS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL COMMERCIAL DISTRIBUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL COMMERCIAL DISTRIBUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL COMMERCIAL DISTRIBUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL DIRECT-TO-PATIENT/HOME DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL DIRECT-TO-PATIENT/HOME DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL DIRECT-TO-PATIENT/HOME DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMANITARIAN & NGO SUPPLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL HUMANITARIAN & NGO SUPPLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMANITARIAN & NGO SUPPLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL SPECIALTY PHARMACY FULFILLMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL SPECIALTY PHARMACY FULFILLMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL SPECIALTY PHARMACY FULFILLMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL VACCINATION CAMPAIGNS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL VACCINATION CAMPAIGNS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL VACCINATION CAMPAIGNS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL BLOOD BANKS & PLASMA CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL BLOOD BANKS & PLASMA CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL BLOOD BANKS & PLASMA CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL CLINICAL TRIAL SITES & DEPOTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL CLINICAL TRIAL SITES & DEPOTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL CLINICAL TRIAL SITES & DEPOTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL CMOS & CDMOS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL CMOS & CDMOS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL CMOS & CDMOS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL CROS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL CROS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CROS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL PHARMA & BIOTECH MANUFACTURERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL PHARMA & BIOTECH MANUFACTURERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL PHARMA & BIOTECH MANUFACTURERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL EMERGING BIOTECH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL EMERGING BIOTECH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL EMERGING BIOTECH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL LARGE PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL LARGE PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL LARGE PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL RETAIL & SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL RETAIL & SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL RETAIL & SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL VACCINATION CENTERS & PUBLIC HEALTH AGENCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL VACCINATION CENTERS & PUBLIC HEALTH AGENCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL VACCINATION CENTERS & PUBLIC HEALTH AGENCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 308. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2032 (USD MILLION)
  • TABLE 312. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2032 (USD MILLION)
  • TABLE 314. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 316. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 318. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2032 (USD MILLION)
  • TABLE 320. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2032 (USD MILLION)
  • TABLE 322. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 326. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 330. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 332. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 334. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2032 (USD MILLION)
  • TABLE 336. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 338. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2032 (USD MILLION)
  • TABLE 340. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2032 (USD MILLION)
  • TABLE 342. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 344. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2032 (USD MILLION)
  • TABLE 348. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 350. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 352. LATIN AMERICA COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 354. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 356. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 357. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 358. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 359. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 360. EUROPE COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTI